Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease
Résumé
Aging can lead to decline in cognition, notably due to neurodegenerative processes overwhelming the brain over time. As people live longer, numerous concerns are rightfully raised toward long-term slowly incapacitating diseases with no cure, such as Alzheimer's disease. Since the early 2000's, the role of neuroinflammation has been scrutinized for its potential role in the development of diverse neurodegenerative diseases notably because of its slow onset and chronic nature in aging. Despite the lack of success yet, treatment of chronic neuroinflammation could help alleviate process implicated in neurodegenerative disease. A growing number of studies including our own have aimed at the endocannabinoid system and unfolded unique effects of this system on neuroinflammation, neurogenesis and hallmarks of Alzheimer's disease and made it a reasonable target in the context of normal and pathological brain aging. Alzheimer's disease (AD) is the most common neurodegenerative disease and accounts for the majority of diagnosed dementia after age 60. It is estimated to currently affect between 20 and 30 million people worldwide with an incidence of the disease between 3 and 30% over the age of 60 [1]. As life expectancy increases, the prevalence of AD and its burden on healthcare is very likely to increase dramatically in the next few decades. Currently available drugs do not reverse or stop the progression of the disease, but only relieve certain cognitive symptoms and thus provide no cure for this growing health and economic concern. Alzheimer's disease
Domaines
Santé publique et épidémiologie
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...